Conversely, in preclinical models of pulmonary hypertension, pharmacological activation of GCN2 by halofuginone has been shown to attenuate vascular remodeling, oxidative stress, and inflammation—supporting a protective role in this pathological setting [94,126,127]. The gene discussed is EIF2AK4; the disease is pulmonary arterial hypertension.